

## Health Workers' Webinar on COVID-19 Vaccines

The discussion points are derived from the questions received from the Health Workers

*Questions received from the Health Sector institutions to be addressed during the webinar*

Discussion Point	Question	Respondent
1. National Deployment Vaccination Plan	What are the details around the vaccine roll-out plans? – <ul style="list-style-type: none"> <li>• When will these be made available?</li> <li>• When to start vaccination? (Medical aid funds need to prepare and communicate with members).</li> </ul>	Ms Shoopala
	Do medical aid funds have an assurance that their eligible members will be vaccinated (per MOHSS vaccination priority list) – seeing that they pay for this voluntarily ...as opposed to receiving this free of charge?	
	Total cost of the vaccine (including procurement, transport and storage, logistics, distribution etc. costs)? About N\$ 500 000 000 (five hundred million Namibia Dollars)	Ms Nakamhela
2. Stakeholder involvement in the Roll out of the Vaccine	Why does the MoHSS not include the assistance of the private sector in the entire COVID-19 effort and vaccine rollout? (Even the attached notice of this information session excluded the private sector).	Ms Shoopala
3. Who is involved in the vaccination apart from the MoHSS?	Who will be allowed to vaccinate (in addition to the MOHSS structures)? Doctors, Pharmacies, privately registered Nurses, private Hospitals, Nurses working in clinics of large employer groups (i.e., the mines / breweries etc.). – Refer to	Ms Shoopala/Dr Kandetu

	my earlier question about the role of the private sector per bullet point 2 above.	
4. Vaccination Cards	Will vaccination passports be issues to those who have been successfully vaccinated? Will these documents be internationally acceptable (ie. to access other countries)?	Dr Mugala
5. Monitoring of vaccine beneficiaries as they receive the second dose and	Persons who need to receive a second vaccine boost (per regimen) will have to be monitored and reminded to get this in time. Who will monitor this?	Ms Shoopala
6. Liability of patients that develops side effects due to COVID-19 vaccine	Who will monitor adverse events/reactions in persons just vaccinated?	
7. Astra Zeneca: <ul style="list-style-type: none"> <li>Does it protect against the new COVID-19 Variant?</li> </ul>	The Astra Zeneca vaccine apparently does not properly protect against the SA COVID-19 variant. Namibia will receive a large amount of this vaccine from COVAX Facility. Why are we buying this still, whilst the RSA has switched to another type of vaccine?	Dr Katjitae
<ul style="list-style-type: none"> <li>Effectiveness of Astra Zeneca on new COVID-19 variant</li> </ul>	What happens if the Astra Zeneca vaccine proves to be ineffective against the South African strain?	Dr Bruwer
	<ul style="list-style-type: none"> <li>a. Will members have to receive a second vaccination?</li> <li>b. Who will be responsible for such additional costs since medical aid funds will only pay for the costs of 1 x vaccination regimen per beneficiary older than 16 years, per year?</li> </ul>	Ms Shoopala
<ul style="list-style-type: none"> <li>The Costs involved</li> </ul>	Is the costing for the Astra Zeneca vaccine the same as previously communicated or does this come at a discounted price?	Ms Nakamhela
<ul style="list-style-type: none"> <li>The consignment destined to Namibia and shelf life</li> </ul>	Does Namibia have any guarantees that the Astra Zeneca batch obtained via the Covax initiative does not include any of the vaccines rejected by the South African Government. If indeed the Namibian consignment contains	Ms Nakamhela

	vaccines originally destined for the SA government, to what extent has the expiry date been compromised and what guarantees are given regarding the cold chain management?	
8. Effectiveness of vaccines	How effective is the vaccine that will be used? For how long will protection last?	Dr Konstantinus
9. Long term side effects	Any long-term side effects/safety concerns?	Dr Katjita
10. Liability of patients that develops side effects due to COVID-19 vaccine	To what extent can anybody/medical aid funds specifically be held liable for patients developing adverse side effects as a result of having received the vaccination	Ms Botes